beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies (Q44277892)

1 December 2017

beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies (English)

1 reference

1 December 2017

1

1 reference

1 December 2017

Vincenza Andrisano

4

0 references

author name string

Carlo Bertucci

series ordinal

2

1 reference

PubMed ID

12527333

1 December 2017

Vanni Cavrini

series ordinal

3

1 reference

PubMed ID

12527333

1 December 2017

language of work or name

English

0 references

publication date

1 February 2003

1 reference

1 December 2017

Biochemical Pharmacology

1 reference

1 December 2017

65

1 reference

1 December 2017

3

1 reference

1 December 2017

407-416

1 reference

The cholinergic hypothesis of geriatric memory dysfunction

1 December 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Acetylcholinesterase accelerates assembly of amyloid-beta-peptides into Alzheimer's fibrils: possible role of the peripheral site of the enzyme.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Translating cell biology into therapeutic advances in Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Stable complexes involving acetylcholinesterase and amyloid-beta peptide change the biochemical properties of the enzyme and increase the neurotoxicity of Alzheimer's fibrils.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Clearing the brain's amyloid cobwebs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Amyloid diseases: abnormal protein aggregation in neurodegeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Presenilin, Notch, and the genesis and treatment of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

A structural motif of acetylcholinesterase that promotes amyloid beta-peptide fibril formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Amyloid fibrillogenesis: themes and variations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Thioflavine T interaction with synthetic Alzheimer's disease beta-amyloid peptides: detection of amyloid aggregation in solution

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

[18] Quantification of β-sheet amyloid fibril structures with thioflavin T

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

A new and rapid colorimetric determination of acetylcholinesterase activity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

The alpha-helical to beta-strand transition in the amino-terminal fragment of the amyloid beta-peptide modulates amyloid formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Direct conversion of an oligopeptide from a beta-sheet to an alpha-helix: a model for amyloid formation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Measurement of the β-sheet-forming propensities of amino acids

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Importance of environment in determining secondary structure in proteins

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Circular dichroism studies of acetylcholinesterase conformation. Comparison of the 11 S and 5.6 S species and the differences induced by inhibitory ligands.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

An improved method of preparing the amyloid beta-protein for fibrillogenesis and neurotoxicity experiments.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Assembly of A beta amyloid protofibrils: an in vitro model for a possible early event in Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Acetylcholinesterase noncovalent inhibitors based on a polyamine backbone for potential use against Alzheimer's disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Acetylcholinesterase inhibitors: SAR and kinetic studies on omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)methyl]aminoalkoxyaryl derivatives

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Hexahydrochromeno[4,3-b]pyrrole derivatives as acetylcholinesterase inhibitors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

The 'aromatic patch' of three proximal residues in the human acetylcholinesterase active centre allows for versatile interaction modes with inhibitors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Quaternary ligand binding to aromatic residues in the active-site gorge of acetylcholinesterase

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Interaction of fluorescence probes with acetylcholinesterase. Site and specificity of propidium binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Fasciculin 2 binds to the peripheral site on acetylcholinesterase and inhibits substrate hydrolysis by slowing a step involving proton transfer during enzyme acylation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Donepezil for Alzheimer's disease: pharmacodynamic, pharmacokinetic, and clinical profiles.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Donepezil use in Alzheimer disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

A comparative study in rats of the in vitro and in vivo pharmacology of the acetylcholinesterase inhibitors tacrine, donepezil and NXX-066.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Comparative studies of huperzine A, E2020, and tacrine on behavior and cholinesterase activities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Carbamylation and binding constants for the inhibition of acetylcholinesterase by physostigmine (eserine)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Novel therapeutic strategies provide the real test for the amyloid hypothesis of Alzheimer's disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

A monoclonal antibody against acetylcholinesterase inhibits the formation of amyloid fibrils induced by the enzyme

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

Acetylcholinesterase inhibitors: synthesis and structure-activity relationships of omega-[N-methyl-N-(3-alkylcarbamoyloxyphenyl)- methyl]aminoalkoxyheteroaryl derivatives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-2952%2802%2901514-9

10.1016/S0006-2952(02)01514-9

7 January 2021

Identifiers

DOI

1 reference

1 December 2017

1 reference

PubMed ID

12527333